This Week in Cardiology cover image

Nov 17 2023 This Week in Cardiology

This Week in Cardiology

00:00

Semaglutide: A Potential Game-Changer in Treating Obesity and Cardiovascular Disease

This chapter explores the results of the select trial testing semaglutide as a disease-modifying agent for patients with obesity and atherosclerotic cardiovascular disease. Semaglutide was found to significantly reduce cardiovascular risk, induce weight loss, and improve other health markers. However, concerns about adverse events, cost, and access are also discussed.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app